{
    "clinical_study": {
        "@rank": "33419", 
        "acronym": "REGARD", 
        "arm_group": {
            "arm_group_label": "Regorafenib", 
            "arm_group_type": "Experimental", 
            "description": "Regorafenib, 40 mg tablets"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label phase III study of regorafenib in patients with metastatic colorectal\n      cancer (mCRC) who have progressed after all approved standard therapy. The purpose of this\n      study is to provide additional information about the safety profile of Regorafenib."
        }, 
        "brief_title": "Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects >/= 18 years of age\n\n          -  Life expectancy of at least 3 months\n\n          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum\n\n          -  Subjects with metastatic colorectal cancer (Stage IV)\n\n          -  Progression during or within 3 months following the last administration of approved\n             standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan,\n             bevacizumab and cetuximab/panitumumab if KRAS WT (WT: wild-type i.e. no KRAS\n             mutation)\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of </= 1\n\n          -  Adequate bone marrow, liver and renal function as assessed by the following\n             laboratory requirements\n\n          -  Women of childbearing potential and men must agree to use adequate contraception\n             since signing of the inform consent (IC) form until at least 3 months after the last\n             study drug administration\n\n        Exclusion Criteria:\n\n          -  Prior treatment with regorafenib\n\n          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days\n             before start of study drug\n\n          -  Pregnant or breast-feeding subjects\n\n          -  Congestive heart failure >/= New York Heart Association (NYHA) class 2\n\n          -  Myocardial infarction less than 6 months before start of study drug\n\n          -  Ongoing infection > Grade 2 Common Terminology Criteria for Adverse Events (CTCAE) v.\n             4.0\n\n          -  Renal failure requiring hemo-or peritoneal dialysis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853319", 
            "org_study_id": "16754"
        }, 
        "intervention": {
            "arm_group_label": "Regorafenib", 
            "description": "160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)", 
            "intervention_name": "Regorafenib (BAY73- 4506)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Regorafenib", 
            "Metastatic colorectal cancer"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06500"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antalya", 
                        "country": "Turkey", 
                        "zip": "07059"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Balcali", 
                        "country": "Turkey", 
                        "zip": "01330"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bursa", 
                        "country": "Turkey", 
                        "zip": "16059"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gaziantep", 
                        "country": "Turkey"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Instanbul", 
                        "country": "Turkey", 
                        "zip": "34662"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "34390"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izmir", 
                        "country": "Turkey", 
                        "zip": "35100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kayseri", 
                        "country": "Turkey"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Samsun", 
                        "country": "Turkey", 
                        "zip": "55139"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health Turkey General Directorate of Pharmaceuticals and Pharmacy", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Number of participants with adverse events which caused withdrawal, dose reduction, interruption or discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Number of death", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Number of participants with serious adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853319"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}